SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today its next-generation Dexcom G7 CGM System ...

SAN DIEGO & EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 ...

Dexcom has been abuzz this year amid the European approval—and submission for FDA approval in the U.S.—for its next-generation G7 continuous glucose monitoring system, which promises more accurate ...

Glucose monitoring specialist Dexcom announced it received FDA clearance for its G7 15 Day continuous glucose monitoring (CGM) system for people 18 and older with type 1, type 2 and gestational ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...

Dexcom G7 is available for people with all types of diabetes ages two years and older, giving more Canadians than ever access to a simple, accurate1 and effective diabetes management solution Dexcom ...

Dexcom G7 offers new features with a 60% smaller, discreet wearable patch. The Food and Drug Administration (FDA) has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System ...

Pop icon and actor Nick Jonas is burnin’ up for Dexcom’s new continuous glucose monitoring system in the company’s upcoming Super Bowl ad. Dexcom announced this week that Jonas, who has type 1 ...

DexCom, Inc.'s DXCM next-generation Dexcom G7 Continuous Glucose Monitoring System has been approved by Health Canada. This department operates under the Government of Canada and is responsible for ...

In addition to improved accuracy, the Dexcom G7 15 Day allows for 15.5 days of wear. The Food and Drug Administration (FDA) has cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM) system ...